Genus

Preliminary Results

Year Ended 30 June 2026

Significant strategic progress and £60m share buyback announced

Disclaimer

This presentation has been prepared by Genus plc ("Genus" or "the Company") and has not been independently verified. Genus is solely responsible for the contents of this document and has taken all reasonable care to ensure that the facts stated herein are true and accurate in all material respects and that there are no material facts the omission of which would make misleading any statement in this document whether of fact or opinion.

While the information contained in this presentation has been provided in good faith, neither the Company, nor any of their advisers, representatives, officers, agents or employees makes any representation, warranty or undertaking, express or implied, in respect of this presentation and no responsibility or liability is accepted by any of them as to the accuracy, completeness or reasonableness of the information provided. The issue of this presentation to the recipient does not create any obligation on the part of the issuer to provide the recipient access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in this presentation or any additional information which may become apparent. The recipient should conduct its own investigation into the Company and of any other information contained in the presentation.

This presentation is for information purposes only and does not constitute, and shall not be interpreted as, either an offer for sale, prospectus, invitation to subscribe for shares or debentures in the Company, or as the basis of a contract.

This presentation has been prepared on the basis that it will only be made available to investment professionals and is thereby exempt from the provisions of s21 of the Financial Services and Markets Act 2000.

Overview & Headlines

Jorgen Kokke

Chief Executive Officer

What Genus does

We produce and sell elite animal genetics to farmers. Our genetics constitute less than 2% of a farmer's typical cost base

Our animals exhibit valuable traits such as increased feed conversion, growth rates and robustness

This helps our customers raise healthier animals that produce more high-quality protein per unit of input

Our products therefore improve farmer profitability and reduce the environmental impact of animal protein production

FY26: Significant progress & additional shareholder return

- **Excellent financial performance:** Strong growth in adj. PBT (+35%) and adj. EPS (+35%) and very strong free cash flow generation (£62m)
- **Further PRP milestones:** Approvals and/or positive determinations secured in Argentina, Canada, Uruguay and Peru; commercialisation process beginning in selected Latin American countries
- **Localised PIC platform in China;** Joint venture formation crystallises value and accelerates the long-term growth opportunity
- **Substantially strengthened balance sheet with additional capital returned to shareholders:** £60m share buyback expected to be completed in FY27 in addition to 10% Full Year dividend growth

Financial Results

Andy Russell

Chief Financial Officer

Strong FY26 financial performance

Revenue	Adj. PBT[1]	Adj. EPS[1]
£658.1m (-2%)	£100.2m (+35%)	110.3p (+35%)

Free Cash Flow[1]	Adj. Leverage[1]	Adj. ROIC[1]
£62m Conversion 94%	0.4x (FY25: 1.5x)	18.4% (FY25: 15.0%)

1. Includes £5.6m milestone receipt from BCA

Financial KPIs: Good overall performance; regional/product variation

Genus PIC

Adj. Royalty Revenue Growth[1,2]	Adj. Op. Profit[3]	Adj. Op. Profit Margin[3,4]
+5%	£130.8m (+17%)	30.9% (+330bps)

NAM	+1%
LATAM	+3%
EMEA	+7%
ASIA	+10%
JVs	+19%

Genus ABS

Sexed Volume	Adj. Op. Profit	Adj. Op. Profit Margin[4]
8.8m (+2%)	£22.9m (+17%)	7.5% (+130bps)

NB: In actual currency and includes Joint Ventures unless specified; growth rates are compared to the prior year period

1. Adjusted Royalty Revenue is a new APM which removes 100% of PIC China royalty revenue from reported revenue and adds back 49% of our JV royalty revenues
2. Constant currency
3. Includes £5.6m milestone receipt from BCA
4. Excludes our share of profits from Joint Ventures

Strong growth in Group adj. operating profit inc. JVs

Group adjusted operating profit inc. JVs £m



Adj. operating profit inc. JVs waterfall £m



- Group adjusted operating profit grew 25%
- Very strong PIC adj. profit growth, driven by PIC China (7 months up £5m year on year; 5 months as a 49% JV), LATAM, and £5.6m milestone receipt from BCA (vs £3.7m in FY25)
- Good ABS adj. profit growth, driven predominantly by VAP benefits
- Group adj. operating profit margin[1] up 380bps to 17.6% (+350bps to 16.8% excluding the BCA milestones in FY25 and FY26)

1. Adjusted Operating Margin includes joint ventures profit
2. In constant currency calculated by restating the results for the year ended 30 June 2025 at the average exchange rates applied to adjusted operating profit for the year ended 30 June 2026.
3. Other PIC and ABS contains FX translation differences

Genus PIC: Strong adj. operating profit growth

PIC adjusted operating profit inc. JVs bridge £m



- Adj. operating profit inc. JVs increased 17% to £130.8m at a 30.9% margin (16% growth & 29.3% margin exc. BCA milestones)
- Strong performance in Latin America driven by high breeding stock sales
- Growth in other trading regions: strong growth in S.E. Asia and PIC China offset by H2 customer disease challenges in North America
- £5.6m milestone payment from BCA on formation of joint venture in China (vs £3.7m in FY25)
- Excluding the BCA milestone, underlying PRP costs increased £1.5m
- Within global production: non-recurring input cost benefit in H1 (£2.8m) and farm sale in H2 (£1.9m)
- £1.3m FX tailwind in FY26

1. Adjusted operating margin excludes joint ventures
2. Bridge items are in constant currency and calculated by restating the results for the year ended 30 June 2025 at the average exchange rates applied to adjusted operating profit for the year ended 30 June 2026. The FX difference is included within FX / Other

Genus PIC: Strong joint venture performance

	Agroceres PIC		PIC China[1]	
	Royalty Revenue Growth	Adj. Op. Profit	Royalty Revenue Growth	Adj. Op. Profit
Entire Entity	+7%	£38.9m (+56%)	+52%	£15.2m (+81%)
Genus Share of Adj. Op. Profit	Genus Share of Adj. Op. Profit	£19.1m (+56%)	Genus Share of Adj. Op. Profit[1]	£12.2m (+45%)

NB: Constant currency unless specified; growth rates are compared to the prior year period

1. JV formed in January 2026; prior to this, PIC owned 100% of PIC China. Genus share of profit represents 7 months at 100% and 5 months at 49%

Genus ABS: Continued profit improvement

ABS adjusted operating profit bridge
£m



- Adjusted operating profit increased 17% to £22.9m at a 7.5% margin
- VAP continued to be the major driver of ABS profit growth; £9.0m of benefit realised in FY26 comprising £2.0m of annualised Phase 2 benefits and £7.0m of in-year Phase 3 benefits
- Phase 3 initiatives achieved £9.0m of annualised benefit
- Sexed growth offset by challenging dairy volume from adverse market conditions
- Bovine product development costs increased £3.6m, as expected, due to higher depreciation

1. Adjusted operating margin excludes joint ventures
2. Bridge items are in constant currency and calculated by restating the results for the year ended 30 June 2025 at the average exchange rates applied to adjusted operating profit for the year ended 30 June 2026. The FX difference is included within FX / Other

Significant continuing investment in R&D

Genus research and product development[1]

% of Genus revenue



Genus continues to invest substantially in research and product development

Porcine product development

% of Porcine revenue



Lower product development spend primarily due to commodity favourability

Increased underlying investment in PRP costs; PRP costs expected to increase further in FY27

Genus research

% of Genus revenue



Lower research expenditure, as planned

Spend expected to grow slightly in FY27 but remain below 3% of Group revenue

Bovine product development

% of Bovine revenue



Higher dairy bull depreciation from prior period investments and the impact of De Novo acquisition

1. The view of PD spend excludes payments received by PIC from BCA totalling £3.7m in FY25 and £5.6m in FY26

Statutory Income

	FY26 £m	FY25 £m	Change £m
Adjusted operating profit	94.8	81.1	13.7
Net IAS 41 valuation mvmt on biological assets	12.8	(13.3)	26.1
Amortisation of acquired intangible assets	(4.1)	(5.6)	1.5
Impairment of goodwill	0.0	(1.5)	1.5
Share-based payments	(10.4)	(6.9)	(3.5)
Exceptional items	(5.8)	(11.4)	5.6
Operating profit	87.3	42.4	44.9
Share of post-tax profit of JVs and associates	34.7	9.1	25.6
Other gains and losses	204.3	(4.2)	208.5
Net finance costs	(15.8)	(18.8)	3.0
Profit before tax	310.5	28.5	282.0
Taxation	(25.0)	(9.2)	(15.8)
Profit after tax	285.5	19.3	266.2

Non-cash impacts

- £12.8m increase in net IAS 41 biological assets primarily driven by porcine (FY25: £13.3m decrease primarily due to bovine)

Exceptional items

- £5.8m expense (FY25: £11.4m expense); primarily from VAP restructuring costs

Other gains and losses

- £204.1m gain on deconsolidation of PIC China following formation of the JV with BCA

Net finance costs

- £15.8m expense (FY25: £18.8m expense) reflecting lower average borrowing (strong cash generation and lower lease debt) and lower average interest rates

Taxation

- Statutory tax rate of 11.2% (FY25: 36.7%)
- Adjusted tax rate of 27.2% (FY25: 27.5%)

Continued strong Free Cash Flow generation

Free cash flow[1] bridge
Actual currency (£m)



- Very strong Free Cash Flow generation of £62.0m
- Significant adj. EBITDA increase of £11.1m and £10.0m higher JV dividends from Agroceres
- Underlying negative working capital movement of £15.3m primarily due to strong improvement in bovine inventory and receivables in the prior year period
- Lower exceptional cash payments
- Free Cash Flow expected to be lower in FY27 due to the impact of PIC China joint venture formation, modest capex increase and £5.6m BCA milestone in FY26

1. See appendix for detailed cash flow. Free cash flow excludes £12.1m Withholding tax on PIC China 51% disposal as this is netted within disposal proceeds below free cash flow.

Strong financial position – leverage reduced to 0.4x

Net debt bridge

Actual currency (£m)



Significant Net Debt reduction

- Net debt decreased to £71.8m at 30 June 2026
- Leverage[1,2] reduced to 0.4x due to £62m FCF generation and £114m debt benefit from PIC China transaction (98m net cash and £16m lower lease debt)

Improved Return on Adj. Invested Capital

- ROIC[1] improved to 18.4% (FY25 15.0%[3])

10% growth in Full Year dividend

- Proposed full year dividend of 35.2p reflects 32% payout of adj. EPS, in-line with stated 30-40% payout policy

1. 12 month rolling leverage and ROIC
2. Net Debt to EBITDA as defined under our debt facility agreement
3. FY25 restated from 14.7% ROIC to remove biological asset fair value uplifts in Joint Ventures
4. £97.7m PIC China net cash proceeds is made up of £111.0m June cash received net of withholding tax, -£8.9m cash retained within the Joint Venture, -£4.4m transaction costs

FY26 Normalisation

Actual currency (£m)

	FY26							
£m	Reported	Less: PIC China Reported	49% of China	Less: BCA Milestone	Interest & Hedging	Genus pro-forma	Less: PIC One-Off Production Benefit	Normalised
Revenue	658.1	(30.1)	-	-	-	628.0	-	628.0
Adj. OP ex-JVs	94.8	(9.8)	-	(5.6)	(0.9)	78.5	(4.7)	73.8
Share of JVs Profit Before Tax	21.2	(2.4)	7.5	-	-	26.3	-	26.3
Adj. OP inc-JVs	116.0	(12.2)	7.5	(5.6)	(0.9)	104.8	(4.7)	100.1
Net Finance Costs	(15.8)	-	-	-	6.0	(9.8)	-	(9.8)
Adj. Profit Before Tax	100.2	(12.2)	7.5	(5.6)	5.1	95.0	(4.7)	90.3

FY26 Normalisation

PIC China impacts

- Milestone receipt of £5.6m in FY26 (£3.7m in FY25)
- PIC China deconsolidation; FY26 impact ~£4.7m
- Potential net finance cost benefits from lower average net debt
- Hedging gain, in relation to PIC China transaction, of £0.9m in FY26

PIC impacts

- Non-recurring input cost benefit in H1 (£2.8m) and farm sale in H2 (£1.9m)

FY27 considerations

- ABS VAP Phase 3 run-rate benefits offset by higher bovine product development costs
- Higher porcine product development and PRP spend
- £60m share buyback programme

1. Milestone payment received from the Group's Chinese partner, BCA, upon SASAC approval for the formation of the Group's porcine joint venture in China

Capital Allocation Performance

Capital Allocation Framework

Maintain a strong balance sheet →
target leverage range of 1.0x to 2.0x

1	Organic Growth Opportunities	Invest in compelling organic profit growth opportunities that can deliver strong returns
2	Ordinary Dividends	Progressive 30-40% dividend payout funded by organic FCF generation
3	Inorganic Growth Opportunities	M&A subject to strict financial and strategic criteria
4	Surplus Capital Returns	Distribute surplus capital to shareholders

FY26 Performance

0.4x	Leverage at June 2026
£73m (11%)	R&D spend (% of group revenue)
35.2p	FY26 dividend 32% payout; 10% growth
~	Continued monitoring
£60m	Share buyback expected to be completed in FY27

Strategic Progress

Jorgen Kokke

Chief Executive Officer

Strategic Priorities: Continued focus and momentum

1. Continued growth in porcine, accelerated growth in China

- PIC Global: good royalty revenue growth and strong adjusted operating profit growth
- PIC China: successful formation of strategic porcine joint venture in China

2. Successfully commercialise PRP and deliver attractive returns from R&D

- PRP approvals and/or positive determinations secured in Argentina, Canada, Uruguay and Peru
- Commercialisation process beginning in certain Latin American countries

3. Drive greater value from bovine

- VAP Phase 3 achieved £9m of annualised benefit
- ABS is leaner, with a strong product portfolio and a deep pool of talent
- Double-digit margin ambition in the medium term

1: Compounding PIC royalty revenue

Compounding royalty revenue growth…

Constant currency £m



4 year CAGR

NAM	+4%
LATAM	+8%
EMEA	+6%
Asia	+12%
JVs[1]	+12%

…with a proven revenue model that stabilises earnings and drives customer loyalty

Royalty Model

- Aligns PIC and Customer Benefits/Value
- Incentivises more frequent genetic updates
- Independent of commodity prices
- Fosters ongoing relationship with customer
- Generates more steady revenue/profit

Adjusted Royalty Revenue[2]

£197m

(4 yr CAGR +6%[3])

NB: Regions exclude Joint Ventures which are reported separately
1. 49% share of JV royalty revenue
2. Adjusted Royalty Revenue is a new APM which removes 100% of PIC China royalty revenue from reported revenue and adds back 49% of our JV royalty revenues
3. Constant currency

1: Strong PIC China, Joint Venture formed

Strong FY26 (despite declining pork prices)

100% entity; Constant Currency £m



Positive start to joint venture

Positive, collaborative start to the JV relationship with BCA

Continuing to win new royalty customers despite the continuing challenging environment for Chinese pork producers

We estimate market share expansion from 3.4% (FY25) to 5.4% (FY26)

2: Approvals / Favourable Determinations in Argentina, Canada, Uruguay and Peru

Commercialisation process beginning in selected Latin American countries

Approved/favourable determination

Peru	June 2026
Uruguay	March 2026
Canada	January 2026
Argentina	July 2025
U.S.A.	April 2025
Dominican Republic	March 2025
Brazil	April 2024
Colombia	October 2023

Key markets in process

Mexico

Japan

China



The review and approval of PRP for use in human consumption is through new regulatory processes. Timelines for these regulatory processes are difficult to determine and may vary based upon additional regulatory questions raised under the review process or varying response times from regulators around the world

3: VAP completing; focus moving to commercial and operational excellence

VAP Phase 1 & 2:

Adj. Op. Profit Benefit	Exceptional Cost
£21m	£12.4m

Focus Areas

- Unified global leadership
- Pricing governance & value capture
- Selective globalisation
- Product allocation & mix management

VAP Phase 3:

FY26 Adj. Op. Profit Benefit	Annualised Adj. Op. Profit Benefit	FY26 Exceptional Cost
£7m	£9m	£8.2m

Focus Areas

- Reshaping ABS go-to-market
- Improve service recovery

3: ABS journey to medium term double digit operating margins

Foundation set by VAP; Clear strategy for growth beyond FY27

ABS Global

Revenue	Adj. Op. Profit[1]	Adj. Op. Margin[1]
£300m	£22.9m	7.5%

A leading global bovine genetics company

- Deep global customer relationships
- Aligned with global protein consumption trends
- Experienced, talented team
- Leading Dairy Genetics
- Best-in-class Beef Genetics
- One of only two players with commercial sexing technology
- Significant investment in R&D
- Market leading product sustainability

Drive top-line via Commercial Excellence

- Build a higher performing commercial organization
- Leverage through repeatable processes and systems
- Profitable volume growth

Drive margin via Operational Excellence

- Sustainably expand gross margins
- Employ lean principles, continuous improvement and AI enabled process improvements to create a value stream lead organisation
- Increase customer value, systemic waste elimination, intelligent automation

1. Adjusted operating profit includes joint ventures. Adjusted operating margin excludes joint ventures

Summary & Outlook

Jorgen Kokke

Chief Executive Officer

Summary & Outlook

Strong profit and cash generation

Strategic porcine joint venture formed in China

Further PRP regulatory milestones and commercialisation process beginning in certain Latin American countries

£60m share buyback

FY27 Outlook

Resilient underlying profit growth despite cyclical weakness in key agricultural markets

Group adj. PBT in constant currency to be in line with consensus expectations and moderately higher than normalised FY26 adj. PBT of £90.3m:

- PIC: Moderate adj. operating profit growth from a normalised base
- ABS: Moderate adj. operating profit growth
- Group FY27 adj. PBT to be second half weighted

Strong Free Cash Flow generation

Why Invest In Genus

01

Growing and resilient end-markets

Increasing global demand for animal protein

02

Strong positions, leading products

World-class genetics, a well-invested, global supply chain and wrap-around holistic services

03

Significant white space

Significant addressable market growth through customers gaining market share, capturing more genetic benefit and increasing their use of data and technology

04

Two Transformative growth opportunities

PIC China and the PRRS[1] Resistant Pig

05

Defensible intellectual property

Elite germplasm, substantial proprietary data, patents in gene editing and reproductive biology

1: Porcine Reproductive and Respiratory Syndrome

Q&A

Appendices

Technical Guidance

Area	FY26	FY27 Expected Impacts
Adjusted Income Statement Items		
Net Interest	£15.8m	£9m - £11m
Effective Tax Rate	27.2%	26% - 28%
Foreign Exchange	£3.5m tailwind	£0m - £2m headwind based on current rates; see Appendix
ABS VAP Phase 3 benefit to adjusted operating profit	£7.0m	£2m incremental from run-rate
Actual/Estimated Exceptional Items	£5.8m	£5m - £7m
Cash Flow Statement Items		
Depreciation & Amortisation	£36.1m	£35m - £37m
Actual/Estimated Exceptional Items	£12.5m	£3m - £5m
Biological assets	£1.9m	£(2m) – 2m
Net Capital Expenditure	£16.0m	£24m - £26m
Cash Conversion	94.4%	70% - 80%

Pro Forma: Milestones & PIC China Deconsolidation

Actual currency (£m)

	FY26 H1						
£m	**Reported**	Less: PIC China	49% of China JV & interest savings	Less: Milestone (SASAC[1])	**Genus pro-forma**	Less: PIC One-Off Production Benefit	**Normalised**
Revenue	**335.6**	(25.3)	-	-	**310.3**		**310.3**
Adj. OP ex-JVs	**55.7**	(8.5)	-	(5.6)	**41.6**	(2.8)	**38.8**
Share of JVs Profit Before Tax	**8.7**	0.5	3.9	-	**13.1**		**13.1**
Adj. OP inc-JVs	**64.4**	(8.0)	3.9	(5.6)	**54.7**	(2.8)	**51.9**
Net Finance Costs	**(8.7)**	-	2.9	-	**(5.8)**		**(5.8)**
Adj. Profit Before Tax	**55.7**	(8.0)	6.8	(5.6)	**48.9**	(2.8)	**46.1**

1. Milestone payment received from the Group's Chinese partner, BCA, upon SASAC approval for the formation of the Group's porcine joint venture in China

Pro Forma: Milestones & PIC China Deconsolidation

Actual currency (£m)

FY25 Full Year					
£m	**Reported**	Less: PIC China	49% of China JV & interest savings	Less: Milestone (FDA[1])	**Genus pro-forma**
Revenue	**672.8**	(41.3)	–	–	**631.5**
Adj. OP ex-JVs	**81.1**	(9.0)	–	(3.7)	**68.4**
Share of JVs Profit Before Tax	**12.0**	0.6	4.2	–	**16.8**
Adj. OP inc-JVs	**93.1**	(8.4)	4.2	(3.7)	**85.2**
Net Finance Costs	**(18.8)**	-	6.4	–	**(12.4)**
Adj. Profit Before Tax	**74.3**	(8.4)	10.6	(3.7)	**72.8**

1. Milestone payment received from the Group's Chinese partner, BCA, upon FDA approval of the PRP gene edit for use in the U.S. food supply chain

Free Cash Flow

	FY26 actual £m	FY25 actual £m
Adjusted operating profit inc. JV	**116.0**	**93.1**
Less: JV profit and non-controlling interests	(21.2)	(12.0)
Depreciation and amortisation	36.1	38.7
Adjusted EBITDA	**130.9**	**119.8**
Cash received from joint ventures	16.1	6.1
Working capital	(10.8)	11.3
Biological assets	1.9	1.3
Net capital expenditure	(16.0)	(18.2)
Lease repayments	(12.6)	(14.1)
Adjusted cash generated by operations	**109.5**	**106.2**
Cash conversion %	**94.4%**	**114.1%**
Exceptional items	(12.5)	(24.2)
Pension contributions, provisions & other	(0.6)	(1.6)
Interest and tax paid (exc PIC China WHT)	(34.4)	(39.5)
Free cash flow inc. lease repayments	**62.0**	**40.9**
PIC China 51% disposal net of WHT & costs[1]	97.7	–
Acquisitions, investments & net JV loans	–	(4.3)
Dividends	(21.7)	(21.1)
Net cash flow before non-lease debt repayments	**138.0**	**15.5**

Cash flow history
(£m)



1. £97.7m PIC China net cash proceeds is made up of £111.0m June cash received net of withholding tax, -£8.9m cash retained within the Joint Venture, -£4.4m transaction costs

Exchange Rate Sensitivity

Genus's geographic profile can lead to translational currency impacts

We monitor key rates against GBP

Latest spot rates indicate a £0-£2m negative profit impact for FY27 compared with average FY26 rates

	FY26 Average[1]	FY26 Closing	Spot at 07 Sept 2026	Profit Sensitivity £m[2]
Euro	1.15	1.16	1.17	2.6
Brazilian Real	7.05	6.85	6.95	2.4
Mexican Peso	24.0	23.2	23.0	2.2
US Dollar	1.33	1.33	1.36	1.7
Chinese Yuan	9.38	9.00	9.09	1.2
Russian Rouble	104.2	104.3	116.5	1.1

1. Weighted average exchange rate based on profit before tax
2. 12-month profit before tax impact given a +/- 10% movement in exchange rate, based on FY26 results. FY27 sensitivity may differ based on current trading

Return on Invested Capital

	FY26 £m	FY25 restated[1] £m
Adjusted operating profit inc JV	116.0	93.1
Tax rate	27.2%	27.5%
Adjusted operating profit after tax	84.4	67.5
Equity attributable to owners of the company	766.7	476.1
Add back:		
Net debt	71.8	228.2
Pension liability (net of asset)	4.4	6.9
Related deferred tax	(1.1)	(1.2)
Deduct:		
Fair value uplifts;		
➢ Biological assets (inc JVs)	(237.7)	(207.8)
➢ PIC China Joint Venture	(90.6)	–
Biological assets deferred tax	48.0	49.2
Goodwill	(103.4)	(102.8)
Adjusted invested capital	458.1	448.6
Return on adjusted invested capital	18.4%	15.0%

1. FY25 restated from 14.7% ROIC to remove biological asset fair value uplifts in Joint Ventures

Sustainability

FY26 Milestones

- **Beef on Dairy Life Cycle Assessment:** ABS NuEra Genetics reduce the overall environmental footprint of commercial beef on dairy programmes in the U.S. and U.K. by 4.5% to 8.8%
- **PRP Life Cycle Assessment:** Eliminating PRRS could reduce green house gas emissions by approximately 5% in the U.S.
- **Continued strong genetic improvement** across porcine, dairy and beef
- **Animal weight intensity ratio reduced by 16%** compared to SY25

Animal Weight Intensity Ratio (tCO_2e / animal weight (tonnes))



NB: "SY" refers to the Sustainability Year End which is March 2026
1. Restated, see Annual Report for more details

Porcine Genetic Improvement Index

(US$)

The index measures the marginal improvement in customers' US$ profitability, per commercial pig per year, on a rolling three-year average.

Genomic Bull Net Merit $ Index

The average Net Merit Dollar (NM$) index score of generally available Holstein commercial bulls launched to the market. Performance is reported on a two-year rolling basis, reflecting the typical commercial sales life of a bull. See the Group's Annual Report for more details.

Proportion of Total Porcine Volumes Under Royalty

North America



EMEA



Latin America



Asia



Glossary

Artificial insemination ('AI') Using semen collected from a bull or boar to impregnate a cow or sow when in oestrus. Artificial insemination allows a genetically superior male to be used to mate with many more females than would be possible with natural mating.

ASF African Swine Fever.

Boar A male pig.

CRISPR-Cas 9 Technology which accurately targets and cuts DNA to produce precise and controllable changes to the genome.

CO2e measure used to compare the emissions from various GHGs based on their global-warming potential, by converting amounts of other gases to the equivalent amount of carbon dioxide with the same global warming potential.

Farrow When a sow gives birth to piglets.

FCR Feed conversion ratio.

FDA The United States Food and Drug Administration.

Gender skew The ability to influence the proportion of offspring being of a particular sex.

Genetic gain The change of the genetic make up of a particular animal population in response to having selected parents that excelled genetically for important traits.

Genetic lag The amount of time required to disseminate genetic gain from a nucleus herd to the commercial customer.

Genetic nucleus A specialised pig herd, where Genus PIC keeps its pure lines. Pigs are genetically tested at the nucleus to select the best animals to produce the next generation. This is also referred to as an Elite Farm.

Genomic bull A bull which has been assessed through genomic testing. This typically refers to bulls which have not been progeny-tested.

Genomics The study of the genome, which is the DNA sequence of an animal's chromosomes.

GHG Gases that trap heat in the atmosphere are called greenhouse gases.

Gilt A young female pig, which has not yet given birth.

GGP/GP Great grandparent/grandparent.

In vitro fertilisation ('IVF') The fertilisation of an oocyte (or egg) with semen (outside an animal) in a laboratory for transfer into a surrogate.

Index/Indices A formula incorporating economically important traits for ranking the genetic potential of animals as parents of the next generation.

IntelliGen The technology platform used to process sexed bovine semen for ABS and third-party customers and commercialised by ABS as Sexcel.

Market pig equivalents ('MPE') Refers to a standardised measure of our customers' production of slaughter animals that contain our genetics with genes from each of the sow and boar counting for half of the animal.

Multiplier A producer whose farm contains grandparent sows. The farm crosses together two lines of grandparents, multiplying the number of genetically improved parents that are available for sale.

NuEra The ABS beef breeding programme and index designed to drive the customer's genetic improvement and deliver total system profitability for the beef supply chain.

PRP PRRS Resistant Pig.

PRRSv Porcine Reproductive and Respiratory Syndrome Virus.

PSY Pigs per Sow per Year. The average number of pigs weaned per litter multiplied by the average number of litters farrowed per sow per year.

Scope 1 emissions are emissions that result from directly burning fuels or emissions of GHG from sources owned or controlled by Genus.

Scope 2 emissions are in-direct emissions associated with the use or generation of energy in the form of electricity.

Sexcel The ABS brand of sexed bovine genetics produced using IntelliGen.

Sire The male parent of an animal.

Sire line The male line selected for traits desirable for the market.

Sow A female pig which has given birth at least once.

Straw A narrow tube used to package frozen bull semen.

Terminal boars The male pig that is used to mate with a parent female to produce a terminal pig.

Trait A measurable characteristic that may be a target for genetic selection.

Unit A straw of frozen bull semen or tube/bag of fresh boar semen sold to a customer.